Why Phill Gross And Robert Atchinson’s Adage Capital Partners Gp. Reported Stemline Therapeutics Inc Position?

February 13, 2018 - By Maria Brooks

 Why Phill Gross And Robert Atchinson's Adage Capital Partners Gp. Reported Stemline Therapeutics Inc Position?

Investors sentiment increased to 1.24 in 2017 Q3. Its up 0.24, from 1 in 2017Q2. It increased, as 6 investors sold Stemline Therapeutics, Inc. shares while 19 reduced holdings. 13 funds opened positions while 18 raised stakes. 12.54 million shares or 4.36% more from 12.02 million shares in 2017Q2 were reported.

California State Teachers Retirement reported 35,816 shares. Bnp Paribas Arbitrage accumulated 2,317 shares. Israel-based Sphera Funds Management Limited has invested 0.48% in Stemline Therapeutics, Inc. (NASDAQ:STML). Axa holds 620,546 shares or 0.03% of its portfolio. Consonance L P stated it has 101,420 shares or 0.12% of all its holdings. Sabby Mgmt Limited Liability Com has invested 0.03% in Stemline Therapeutics, Inc. (NASDAQ:STML). Credit Suisse Ag owns 16,756 shares or 0% of their US portfolio. Tower Research Ltd Limited Liability Company (Trc) has invested 0% in Stemline Therapeutics, Inc. (NASDAQ:STML). Deutsche National Bank Ag accumulated 0% or 194,146 shares. Royal Natl Bank Of Canada stated it has 5,089 shares or 0% of all its holdings. Carl Domino reported 0.35% of its portfolio in Stemline Therapeutics, Inc. (NASDAQ:STML). Knott David M, New York-based fund reported 74,992 shares. Geode Cap Mngmt Ltd Llc holds 0% or 172,201 shares. 16,000 are held by State Of Wisconsin Board. Eventide Asset Ltd Liability Corp owns 1.09 million shares.

Since December 15, 2017, it had 0 insider buys, and 3 selling transactions for $422,597 activity. Another trade for 14,040 shares valued at $195,577 was sold by Hoberman Kenneth.

The New Phill Gross And Robert Atchinson’s Adage Capital Partners Gp. Holding in Stemline Therapeutics Inc

Adage Capital Partners Gp. reported SC 13G/A form with the SEC for Stemline Therapeutics Inc. Access it here: 000090266418000959. As reported by Phill Gross And Robert Atchinson’s Adage Capital Partners Gp., the filler owns 5.67% or 1,434,914 shares of the Health Care–company.

Stemline Therapeutics Inc stake is new for [reportingPerson]. Date of activity: December 31, 2017. This shows Phill Gross And Robert Atchinson’s Adage Capital Partners Gp.’s positive view for Stemline Therapeutics Inc.

The hedge fund is investor in the Health Care sector. In the manager’s last 13-F, we saw 12% of Phill Gross And Robert Atchinson’s Adage Capital Partners Gp.’s portfolio is in the sector.

Stemline Therapeutics Inc Institutional Sentiment

Filings show 56 investors own Stemline Therapeutics Inc. The ownership in Q3 2015 is high, at Infinity of the outstanding shares. This is increased by 656031. 10320255 were owned by these investors. 2 funds opened new Stemline Therapeutics Inc stakes, 19 increased positions. There were 14 that closed positions and 18 reduced them.

Eventide Asset Management Llc is an investor bullish on Stemline Therapeutics Inc, owning 735000 shares as of Q3 2015 for 0.38% of its portfolio. Opus Point Partners Management Llc owns 75000 shares or 0.37% of its portfolio. CT Great Point Partners Llc have 1.66% of its portfolio for 475200 shares. Further, Healthcare Value Capital Llc reported stake worth 0.32% of its portfolio. The CA Vhcp Management Llc owns 451400 shares. Stemline Therapeutics Inc is 1.02% of its portfolio.

Business Profile

Stemline Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers. SL-401 consists of IL-3 recombinantly fused to a truncated diphtheria toxin payload. SL-701 is an immunotherapy designed to activate the immune system to attack tumors. SL-701 comprises various short synthetic peptides that correspond to epitopes of targets, including IL-13 receptor subunit alpha-2 (IL-13Ra2), ephrin type-A receptor 2 (EphA2) and survivin, present on brain cancer. SL-801 is an oral, small molecule that reversibly inhibits Exportin-1 (XPO1), also known as Chromosome Region Maintenance-1 (CRM-1), a nuclear transport protein.

SEC Form 13G.

Analysts await Stemline Therapeutics, Inc. (NASDAQ:STML) to report earnings on March, 15. They expect $-0.67 earnings per share, down 19.64 % or $0.11 from last year’s $-0.56 per share. After $-0.68 actual earnings per share reported by Stemline Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -1.47 % EPS growth.

The stock increased 1.30% or $0.2 during the last trading session, reaching $15.55. About 133,051 shares traded. Stemline Therapeutics, Inc. (NASDAQ:STML) has risen 52.65% since February 14, 2017 and is uptrending. It has outperformed by 35.95% the S&P500.

Stemline Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovering, acquiring, developing, and commercialization of proprietary oncology therapeutics in the United States. The company has market cap of $450.51 million. The firm develops SL-401, a targeted therapy directed to the interleukin-3 receptor , which is in Phase II clinical trial for patients with blastic plasmacytoid dendritic cell neoplasm, myeloproliferative neoplasms, and acute myeloid leukemia; and in Phase I clinical trial in combination with other agents for patients with relapsed/refractory multiple myeloma. It currently has negative earnings. It also develops SL-801, a novel oral small molecule reversible inhibitor of a tumor-promoting nuclear transport protein, which is in Phase I clinical trial for the treatment of solid and hematologic cancers; and SL-701, an immunotherapy that is in Phase II clinical trial to attack brain cancer.

Stemline Therapeutics, Inc. (NASDAQ:STML) Ratings Coverage

Among 4 analysts covering Stemline Therapeutics Inc (NASDAQ:STML), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Stemline Therapeutics Inc has $38.0 highest and $11 lowest target. $24.25’s average target is 55.95% above currents $15.55 stock price. Stemline Therapeutics Inc had 13 analyst reports since November 10, 2015 according to SRatingsIntel. The rating was maintained by Jefferies with “Buy” on Monday, June 26. The company was maintained on Monday, June 26 by H.C. Wainwright. As per Wednesday, August 9, the company rating was maintained by H.C. Wainwright. Cowen & Co maintained Stemline Therapeutics, Inc. (NASDAQ:STML) on Wednesday, June 14 with “Buy” rating. The stock of Stemline Therapeutics, Inc. (NASDAQ:STML) has “Buy” rating given on Friday, February 2 by H.C. Wainwright. As per Friday, November 10, the company rating was maintained by H.C. Wainwright. The rating was maintained by H.C. Wainwright with “Buy” on Thursday, December 14. H.C. Wainwright maintained the shares of STML in report on Tuesday, September 12 with “Buy” rating. The stock of Stemline Therapeutics, Inc. (NASDAQ:STML) has “Buy” rating given on Friday, June 23 by Cowen & Co. The company was maintained on Wednesday, November 1 by H.C. Wainwright.

More notable recent Stemline Therapeutics, Inc. (NASDAQ:STML) news were published by: Fool.com which released: “The Clear Reason Why Stemline Therapeutics Inc. Skyrocketed as Much as 33%” on October 31, 2017, also Businesswire.com with their article: “Newman Ferrara LLP Announces Corporate Governance Investigation of Stemline …” published on January 08, 2018, Globenewswire.com published: “Stemline Therapeutics Closes $59.6 Million Public Offering of Common Stock” on January 26, 2018. More interesting news about Stemline Therapeutics, Inc. (NASDAQ:STML) were released by: Globenewswire.com and their article: “Stemline Therapeutics Announces Proposed Public Offering of Common Stock” published on January 22, 2018 as well as Fool.com‘s news article titled: “Here’s Why Stemline Therapeutics Inc. Jumped 23% Higher in October” with publication date: November 06, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.